Soluble and particulate phenylethanolamine N-methyltransferase in hypothalamus of diabetic rats.
Experimental diabetes increases total phenylethanolamine N-methyltransferase (PNMT) activity in the medulla-pons but not in the hypothalamus. In this study diabetes was induced with streptozotocin (65 mg/kg) in male Sprague-Dawley rats. Twenty-eight days after treatment there were no differences in soluble PNMT activity in the hypothalamus of diabetics and controls, but PNMT activity in a membrane-associated (particulate) fraction of hypothalamus was evaluated approximately twofold in tissues of diabetic animals compared with controls. A specific PNMT inhibitor, incubated with tissue extracts of control rats, abolished greater than 90% of particulate PNMT activity in the hypothalamus but reduced soluble PNMT activity in the hypothalamus by only 47%. These findings indicate that membrane-associated PNMT activity in rat hypothalamus differs from soluble hypothalamic PNMT in the in vitro response to an inhibitor and the in vivo response to diabetes and suggest the importance of separating subcellular hypothalamic fractions prior to assay of PNMT.
Chappell
J E
JE
Department of Biology, Virginia Commonwealth University, Richmond 23284-2012.
Stewart
J K
JK
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002498:Centrifugation; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology*; D007031:Hypothalamus / Q000201:enzymology*; D008297:Male; D009994:Osmolar Concentration; D010625:Phenylethanolamine N-Methyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D012995:Solubility; D013347:Subcellular Fractions / Q000201:enzymology
D001552:Benzazepines; C028625:LY 134046; D010625:Phenylethanolamine N-Methyltransferase